Blog

The UK healthtech investment landscape is dynamic and continues to show strong growth, with several key trends shaping its future. Here's a breakdown of what to expect:1. Dominance of AI and Data-Driven Solutions:Continued Surge in AI Investment: AI is the undeniable leader in healthtech investment. Nearly half of all VC investment in UK health in Q1 2025 went to AI-powered startups. This trend is expected to accelerate as AI promises greater precision, accuracy, and autonomy in healthcare, impacting areas like drug discovery, precision medicine, diagnostics (e.g., image analysis for cancer detection), and workflow optimisation.Focus on Health Data Infrastructure: The UK government is investing significantly (up to £600 million) in building a world-leading health data research service. This will unlock vast datasets, enabling scientists to develop better treatments faster and fuel AI-driven innovation. Personalised Medicine and Digital Twins: Advancements in processing multiomic data combined with AI are bringing personalized care closer. "Patient digital twins" offer powerful predictive capabilities and are a promising area for future investment. 2. Increased Investment in Biopharmaceuticals:Within healthtech, biopharmaceuticals remain a highly valuable and populous sub-sector, attracting substantial funding. This includes development of new drugs and therapies, often leveraging AI for accelerated discovery. 3. NHS as a Catalyst and Customer:Digital Transformation of the NHS: The NHS is undergoing a significant digital transformation, with a committed £10 billion investment to bring it into the "digital age" and £2 billion for digital transformation and £520 million for a life sciences innovative manufacturing fund. This creates a huge market and opportunity for healthtech companies that can provide scalable and interoperable solutions.Shift to Value-Based Procurement: There's a growing emphasis on value-based procurement within the NHS, prioritising patient outcomes and long-term value over immediate cost savings. This encourages healthtech companies to develop solutions that demonstrate clear clinical and economic benefits.Streamlined Adoption: Initiatives like the "NHS passport" for proven tools (e.g., AI cancer scanners, wearable devices) aim to speed up the adoption of cutting-edge tech. The NHS Innovation Service also helps facilitate the adoption of new innovations. Challenges Remain: Despite positive initiatives, challenges persist with NHS procurement processes often being slow, fragmented, and lacking transparency. This can still be a significant hurdle for SMEs.4. Addressing Key Healthcare Challenges:Workforce Support and Efficiency: Investment will continue in solutions that alleviate pressure on the healthcare workforce, improve efficiency, and free up staff time. This includes AI-powered tools for administrative tasks, virtual care platforms, and technologies that streamline clinical workflows.Remote Monitoring and Virtual Wards: The success of virtual wards and remote monitoring during and after the pandemic is driving continued investment in technologies that enable patients to receive care at home, reducing hospital stays and easing pressures. Early Diagnosis and Prevention: Healthtech solutions that enable earlier diagnosis (e.g., AI diagnostics) and focus on prevention and managing long-term conditions will see strong investment.5. Evolution of Funding and Ecosystem:Stabilisation of Early-Stage Funding: Early-stage funding (seed and Series A) has stabilized, while most UK venture capital in Q1 2025 went into breakout stage (Series B and C) companies, indicating a maturing ecosystem.Diversification of Funding Sources: UK startups are increasingly looking beyond equity to alternative sources of funding, with debt funding surging.Strong Research Base and Global Attractiveness: The UK's strong research-friendly environment and ability to evaluate technologies for clinical and cost-effectiveness (through institutions like NIHR and NICE) make it an attractive global hub for healthtech.Government Support and Policy: The UK government has a strong commitment to growing the life sciences sector, including healthtech, through various initiatives outlined in its Life Sciences Sector Plan. This includes funding for R&amp;D, manufacturing, and speeding up regulatory processes.6. Regulatory Landscape and Market Access:Ongoing Regulatory Challenges: While there is optimism around proposed international recognition frameworks and efforts to streamline regulation, the complex regulatory landscape remains a significant barrier for many healthtech companies, especially SMEs. Delays in approvals and high compliance costs can extend time to market. Importance of Real-World Evidence: The upcoming NHS Innovation and Adoption Strategy is expected to provide clarity on real-world evidence development, which is crucial for healthtech companies to demonstrate the effectiveness and value of their solutions in real-world settings.In summary, the future of UK healthtech investment will be heavily shaped by the ongoing AI revolution, strong NHS demand for digital transformation, and a continued focus on solving critical healthcare challenges through innovative technologies. While regulatory and procurement hurdles remain, government commitment and a robust research ecosystem position the UK as a key player in the global healthtech landscape.

Future Trends for UK HealthTech Investment

Nelson Advisors HealthTech Macro Trends in 2025

HealthTech founders, while navigating the complex healthcare landscape, often find themselves facing unique challenges related to their venture capital-backed cap tables. A cap table, or capitalization table, details the equity ownership of a company. When VCs enter the picture, it introduces a new dynamic that can lead to significant problems if not managed carefully.Here are 10 common problems for HealthTech founders with VC-backed cap tables:1) Excessive Founder Dilution, Especially Early OnProblem: Founders, particularly in early rounds (pre-seed, seed), sometimes give away too much equity for modest investments, often due to inexperience or a lack of alternative offers. This leaves them with too little ownership by Series A or B, diminishing their motivation and making it less attractive for future VCs who want founders to remain significantly incentivised.HealthTech Nuance: HealthTech often has longer development and regulatory cycles, requiring more funding rounds. If founders dilute too much early, their ownership can dwindle to unsustainable levels over these extended periods. 2) Unplanned Employee Stock Option Pools (ESOPs) and Their DilutionProblem: Not setting aside a sufficient ESOP early enough means that when the time comes to grant options to key hires, this pool often dilutes only the founders and existing shareholders. VCs typically insist that the ESOP is funded before their investment, effectively shifting the dilution burden to pre-existing equity holders.HealthTech Nuance: HealthTech requires highly specialized talent (clinical, regulatory, deep tech). Attracting and retaining these individuals often necessitates competitive equity packages, making a well-planned and sufficiently sized ESOP even more critical. 3) Complicated or "Messy" Cap TablesProblem: Disorganized, error-filled, or overly complex cap tables with too many small shareholders (e.g., numerous angel investors from crowdfunding or early rounds without SPVs) deter future investors. VCs want a clear, manageable ownership structure.HealthTech Nuance: Given the potentially longer timelines and multiple funding rounds, the cap table can become convoluted quickly. Managing numerous small investors, especially if they have disparate interests or are spread across different jurisdictions, adds complexity. 4) Misaligned Investor Expectations and Short-Term FocusProblem: VCs typically seek significant returns within a 5-7 year timeframe. This can create pressure on founders to prioritize rapid growth and a quick exit (IPO or acquisition) over a longer-term vision, sustainable profitability, or deep clinical validation, which is often crucial for HealthTech.HealthTech Nuance: The inherent slowness of healthcare adoption, regulatory hurdles, and the need for rigorous clinical evidence can clash with VC demands for fast returns. This misalignment can lead to strategic disagreements and undue pressure on founders to make decisions that might not be best for the long-term health of the company or its mission. 5) Loss of Control and Undue Investor InfluenceProblem: As VCs invest, they acquire board seats and often demand consent rights over key decisions (e.g., future fundraising, executive hires, M&amp;A). Founders can find themselves with limited operational autonomy.HealthTech Nuance: In a sector requiring deep domain expertise and a nuanced understanding of patient care and clinical workflows, VCs who lack this specific background can push for strategies that are financially driven but clinically or operationally unsound. This can lead to tension and potentially suboptimal outcomes for the product or patient. 6) Punitive Anti-Dilution Provisions for Early InvestorsProblem: While standard, some anti-dilution clauses (especially "full ratchet") can severely penalize founders and later investors in a down-round (a funding round at a lower valuation than the previous one). This can disproportionately increase early investors' ownership at the expense of others.HealthTech Nuance: Down-rounds are more common in a tightening economic climate, and HealthTech, with its longer time-to-revenue, can be more susceptible. Such clauses can make it extremely difficult to raise subsequent rounds or maintain founder equity. 7) Valuation Traps and Unrealistic ExpectationsProblem: Raising at an inflated valuation in a hot market can lead to a "down-round" in subsequent, more conservative funding environments, triggering anti-dilution clauses and significantly diluting founders and earlier non-protected investors.HealthTech Nuance: The "hype cycles" around certain technologies (e.g., AI, digital therapeutics) can lead to overinflated valuations. When the reality of long sales cycles, regulatory burdens, and slow adoption sets in, these valuations can become unsustainable, leading to painful adjustments. 8) Vesting Schedule IssuesProblem: Lack of proper vesting schedules (e.g., 4-year vesting with a 1-year cliff) for founders and key employees means that if someone leaves early, they still walk away with unearned equity, unnecessarily fragmenting the cap table.HealthTech Nuance: Given the interdisciplinary teams and the critical role each early team member plays, clear vesting schedules are essential to ensure long-term commitment and prevent valuable equity from being tied up by inactive parties. 9) Difficulty Attracting Future Investors Due to a "Broken" Cap TableProblem: A cap table where founders are too diluted, too many small investors exist, or there are problematic investor rights can scare off future institutional investors who seek a clear, well-structured ownership.HealthTech Nuance: The "deep tech" nature of many HealthTech solutions means they often require significant, sustained investment. If the cap table isn't appealing, it can impede critical follow-on funding, risking the company's ability to reach commercialization. 10) Lack of Liquidity Planning and Secondary SalesProblem: Founders often focus solely on the next funding round or exit, neglecting the importance of potential secondary sales of their shares. Without a clear strategy or clauses in investor agreements, it can be difficult for founders to achieve any personal liquidity before a full company exit, even after years of work. HealthTech Nuance: Given the longer timelines to IPO or large M&amp;A exits, HealthTech founders might need options for partial liquidity earlier in the journey to manage personal finances or motivate continued commitment. Without proper planning in the cap table, this can be challenging to facilitate. Managing a VC-backed cap table in HealthTech requires a sophisticated understanding of equity dynamics, legal terms, and investor relations. Founders need to be proactive, seek expert advice early, and carefully balance fundraising needs with long-term control and value creation.Nelson Advisors &gt; Healthcare Technology M&amp;ANelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Founders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk﻿</a><a data-mce-href="mailto:paul@nelsonadvisors.co.uk" href="mailto:paul@nelsonadvisors.co.uk" title="paul@nelsonadvisors.co.uk" target="_blank" rel="noopener">paul@nelsonadvisors.co.uk</a>

Capped Out: 10 Common Problems for HealthTech Founders with Venture Capital backed Cap Tables

Attracting a strategic acquirer in the competitive healthtech landscape requires a well-thought-out plan that goes beyond simply building a great product. Here's a 10-point plan for healthtech entrepreneurs looking to position their company for a successful acquisition:1. Deep Market Understanding &amp; Problem/Solution FitIdentify a pressing healthcare pain point: Strategic acquirers want solutions that address critical needs in the healthcare system, whether it's improving patient outcomes, reducing costs, enhancing efficiency, or expanding access to care. Demonstrate clear product-market fit: Show evidence that your product is being adopted, used effectively and delivers tangible value to paying customers (providers, payers, patients, pharma). Case studies, testimonials and strong retention rates are crucial. 2. Clinical Validation &amp; Regulatory CompliancePrioritise robust clinical validation: Strategic buyers, especially in healthtech, highly value solutions with proven clinical efficacy and positive patient outcomes. Invest in rigorous studies and gather data to support your claims.Master the regulatory landscape: Healthtech is heavily regulated. Demonstrate a clear understanding and adherence to relevant regulations (eg. HIPAA, GDPR, FDA approvals, CE markings). A strong compliance track record de-risks the acquisition for the buyer. 3. Scalable Technology &amp; Strong IPBuild a scalable and interoperable platform: Acquirers seek technology that can seamlessly integrate with their existing systems and scale to a larger user base. Focus on robust architecture, modern tech stacks, and interoperability standards (eg. FHIR).Protect your Intellectual Property (IP): Patents, trademarks, and proprietary algorithms are critical assets that enhance your valuation and provide a competitive advantage. Ensure your IP is well-documented and protected. 4. Clear Go-to-Market &amp; Commercialisation StrategyShow a repeatable and efficient customer acquisition model: Acquirers want to see that you have a defined sales channel (B2B, B2C, enterprise, payer partnerships) and a cost-effective way to acquire new customers. Early revenue and consistent growth are key indicators. Demonstrate a path to profitability: While early-stage companies may not be profitable, a clear roadmap to sustainable revenue and positive cash flow is essential. Strategic buyers look for long-term financial viability.5. Robust Data &amp; Analytics CapabilitiesLeverage data for insights and value: Companies offering advanced data analytics, real-time insights, and secure data management systems are highly attractive. Show how your solution uses data to improve decision-making, optimise operations, or personalise care.Ensure data security and privacy: Given the sensitive nature of healthcare data, demonstrate robust cybersecurity measures and compliance with data privacy regulations. 6. Strong Financial Performance &amp; HygieneMaintain accurate and transparent financial statements: Provide clear revenue, expenses and cash flow data. Consistent growth in revenue, strong gross margins, and predictable cash flows are highly valued.Understand your unit economics: Be able to clearly articulate your customer acquisition costs (CAC), customer lifetime value (LTV), and other key financial metrics. Clean books are non-negotiable for due diligence. 7. Strategic Partnerships &amp; Ecosystem IntegrationForm alliances with key industry players: Partnerships with hospitals, payers, pharma companies, or large tech firms (eg. Oracle Health, AWS) provide validation, pilot opportunities, and a clear path to larger markets.Align with acquirer's strategic vision: Research potential acquirers, understand their strategic priorities (eg. press releases, earnings calls) and clearly articulate how your solution complements their existing offerings and contributes to their long-term goals. 8. Experienced &amp; Diverse TeamBuild a strong leadership team: Acquirers assess the talent and experience of your team. A diverse team with clinical, technical, and commercial expertise is highly desirable. Demonstrate a well-prepared team for integration: Show that your team is knowledgeable about the acquisition process and potential integration plans, ensuring a smoother transition post-acquisition.9. Early Relationship Building &amp; NetworkingEngage with corporate development teams early: Don't wait until you're ready to sell. Build relationships with corporate development teams at potential acquirers by attending industry events, leveraging introductions, and showcasing your progress.Establish thought leadership: Publish insightful articles, speak at conferences, and contribute to industry discussions to position your company as an authority in your niche.10. Prepare for Rigorous Due DiligenceAnticipate and organise for due diligence: Acquirers will conduct deep dives into every aspect of your business, including technology, clinical data, financials, legal, and HR. Have all documentation meticulously organized and readily available to avoid delays. Be transparent about risks and mitigation plans: No company is perfect. Be open about any challenges or risks and demonstrate how you are addressing them. This builds trust with potential buyers.By proactively addressing these ten points, healthtech entrepreneurs can significantly enhance their attractiveness to strategic acquirers and maximize their chances of a successful exit.Nelson Advisors &gt; Healthcare Technology M&amp;A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Founders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.ukNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a><a data-mce-href="mailto:paul@nelsonadvisors.co.uk" href="mailto:paul@nelsonadvisors.co.uk" title="paul@nelsonadvisors.co.uk" target="_blank" rel="noopener">paul@nelsonadvisors.co.uk</a>

HealthTech Entrepreneurs 10 Point Plan to attract Strategic Acquirers

Electric medicine, often referred to as electroceuticals or bioelectronic medicine, involves using electrical impulses to modulate the body's nervous system to treat diseases. It targets specific nerves or neural circuits to regulate organ function or alleviate symptoms, offering a non-pharmacological alternative to traditional treatments. &nbsp;&nbsp; Key aspects of Electric Medicine include: Devices: Implantable or non-invasive devices like vagus nerve stimulators, deep brain stimulators, or transcutaneous electrical nerve stimulation (TENS) units.Applications: Treats conditions such as chronic pain, epilepsy, depression, inflammatory disorders, and even heart failure by stimulating nerves like the vagus or peripheral nerves.Mechanism: Works by altering neural signaling to restore balance in bodily functions, often with fewer side effects than drugs.Research: Advances focus on precision, miniaturisation, and mapping neural pathways for targeted therapies.&nbsp; For example, vagus nerve stimulation is FDA-approved for epilepsy and depression, while research explores its use for autoimmune diseases. The field is growing, backed by initiatives like GlaxoSmithKline’s bioelectronics investment and DARPA’s ElectRx program &nbsp;&nbsp; Electric medicine, also known as electroceuticals or bioelectronic medicine, is gaining traction as a transformative HealthTech sub-sector in 2025, driven by its potential to treat chronic diseases through targeted electrical stimulation of the nervous system. Here’s why it’s a key area to watch, along with emerging trends and insights: &nbsp;<figure id="figure-xma4ltnvn7mdgmqadt"><img id="xma4ltnvn7mdgmqadt" src="https://cdn.durable.co/covers/28Url7gOMyCln6By8VLfLOrGxBP7lfDDqokW6rRimJ6uCFVKc5VnYyFzu1Bb0HTk.jpg" alt="" title="" class="object-cover bg-gray-100 rounded-2xl md:rounded-3xl lg:rounded-4xl" style="aspect-ratio: 1/1; object-position: center center;" data-corners="default" data-aspect="1:1" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://cdn.durable.co/covers/28Url7gOMyCln6By8VLfLOrGxBP7lfDDqokW6rRimJ6uCFVKc5VnYyFzu1Bb0HTk.jpg" data-mce-style="aspect-ratio: 1/1; object-position: center center;"></figure> &nbsp; Why Electric Medicine Is a HealthTech Sub-Sector to Watch in 2025 &nbsp;&nbsp; Non-Pharmacological Innovation: Electroceuticals offer a drug-free alternative for conditions like chronic pain, epilepsy, depression, and autoimmune diseases, reducing reliance on pharmaceuticals and minimizing side effects. This aligns with growing patient and provider demand for personalised, less invasive treatments.Market Growth: The global neuro modulation market, encompassing electroceuticals, is projected to grow significantly, with estimates suggesting a CAGR of 12-15% through 2030, driven by advancements in implantable devices and increasing adoption in clinical settings.Technological Advancements: Miniaturized devices, improved biocompatibility, and AI-driven precision in neural mapping are enhancing the efficacy and accessibility of electroceutical therapies. For example, closed-loop systems that adapt stimulation in real-time are improving outcomes for conditions like Parkinson’s disease.Investment and Research Surge: Major players like GlaxoSmithKline, Medtronic, and Boston Scientific, alongside startups, are investing heavily in bioelectronics. Initiatives like DARPA’s ElectRx program and Frost &amp; Sullivan’s spotlight on neuro modulation highlight the sector’s disruptive potential.Regulatory Support: FDA approvals for devices like vagus nerve stimulators for epilepsy and depression, coupled with expanding indications (e.g., inflammation control), are paving the way for broader clinical adoption.Key Trends in Electric Medicine for 2025 &nbsp;&nbsp; Expanded Applications:Chronic Disease Management: Vagus nerve stimulation is being explored for rheumatoid arthritis, Crohn’s disease, and heart failure, leveraging the nerve’s role in regulating inflammation.Mental Health: Non-invasive trans cranial magnetic stimulation (TMS) and trans cranial direct current stimulation (tDCS) are gaining traction for depression, anxiety, and PTSD, with portable devices entering consumer markets.Neurological Disorders: Deep brain stimulation (DBS) advancements are improving outcomes for Parkinson’s, epilepsy, and obsessive-compulsive disorder, with next-gen devices offering precise targeting.Integration with Digital Health:Electroceutical devices are increasingly paired with IoMT (Internet of Medical Things) platforms, enabling remote monitoring and data-driven therapy adjustments. For instance, wearables can track patient responses to stimulation, feeding data to clinicians via cloud platforms.AI and machine learning are optimizing stimulation parameters, enhancing personalization and efficacy. Companies like Subtle Medical are integrating AI with neuro modulation for better outcomes.Non-Invasive Innovations:Non-invasive devices like TENS units and wearable neurostimulators are becoming more sophisticated, offering home-based therapy options. This aligns with the 2025 trend of shifting care outside hospitals, as seen in hospital-at-home programs.Startups like Moodmon are developing AI-powered wearables that combine neuro modulation with mood tracking for mental health conditions.Brain-Computer Interfaces (BCIs):BCIs, a frontier in electroceuticals, are advancing for paralysis, chronic pain, and epilepsy management. In 2025, expect increased discussion around BCIs, though ethical concerns like data ownership will persist.Companies like Neuralink and Synchron are pushing BCI development, with potential applications in restoring motor function or enhancing cognitive therapies.Personalised Neuromodulation:Advances in genomics and real-time analytics are enabling tailored electroceutical therapies. For example, genetic data can inform stimulation protocols, aligning with the broader 2025 trend of hyper-personalised medicine.Real-time health analytics, supported by FHIR standards, will allow clinicians to adjust therapies dynamically based on patient data streams.Challenges to Watch &nbsp;&nbsp; Data Security: As electroceutical devices integrate with digital platforms, protecting sensitive neural data from cyberattacks is critical, especially given healthcare’s vulnerability to breaches costing $11 million on average.Ethical Concerns: BCIs and neural data raise questions about privacy and consent, requiring robust regulatory frameworks.Cost and Access: High costs of implantable devices may limit adoption, though non-invasive options and 3D-printed implants could improve accessibility by 2027.Skills Gap: Implementing advanced electroceuticals requires specialised training, exacerbating the projected 10 million healthcare worker shortage by 2030.Strategic Implications for 2025 &nbsp;&nbsp; Investors: HealthTech investors should focus on startups innovating in non-invasive devices, AI-driven neuromodulation, and BCIs. Sub-sectors like telehealth integrated electroceuticals could command valuation multiples of 5.5-7x revenue.Providers: Hospitals and clinics adopting electroceuticals can enhance patient outcomes and reduce costs for chronic conditions, aligning with value-based care models.Patients: Expect increased access to home-based and wearable electroceutical devices, empowering proactive health management, especially for chronic pain and mental health.&nbsp; Electric medicine is poised to redefine HealthTech in 2025, fuelled by technological breakthroughs, growing clinical evidence, and alignment with personalised and preventive care trends. Its ability to address unmet needs in chronic disease and mental health, combined with digital health integration, makes it a high-impact sub-sector. However, success will depend on navigating data security, ethical, and accessibility challenges. Keep an eye on companies like Medtronic, Neuralink, and AI-driven neuromodulation platforms for game-changing developments. &nbsp;&nbsp; Nelson Advisors &gt; Healthcare Technology M&amp;A &nbsp;&nbsp; Nelson Advisors specialise in mergers, acquisitions &amp; partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>&nbsp; Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a> We share our views on the latest Healthcare Technology mergers, acquisitions &amp; partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>&nbsp; Founders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>&nbsp; #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide &nbsp;&nbsp; Nelson Advisors LLP &nbsp;&nbsp; Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; Contact Us &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&nbsp;&nbsp; <a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>&nbsp; &nbsp; Meet Us &nbsp; Digital Health Rewired &gt; 18-19th March 2025 &gt; Birmingham, UK &nbsp; NHS ConfedExpo &nbsp;&gt; 11-12th June 2025 &gt; Manchester, UK &nbsp; HLTH Europe &gt; 16-19th June 2025, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; 10-11th July 2025, New York, USA &nbsp; World Health Summit 2025 &gt; October 12-14th 2025, Berlin, Germany HLTH USA 2025 &gt; October 18th-22nd 2025, Las Vegas, USA MEDICA 2025 &gt; November 11-14th 2025, Düsseldorf, Germany

Nelson Advisors

Blog

Future Trends for UK HealthTech Investment

Nelson Advisors HealthTech Macro Trends in 2025

Capped Out: 10 Common Problems for HealthTech Founders wi...

HealthTech Entrepreneurs 10 Point Plan to attract Strateg...

Why Electric Medicine Is a HealthTech Sub-Sector to Watch...

The "String of Pearls" M&A Strategy in European BioPharma...